Pimecrolimus cream safe, effective for atopic dermatitis in young children

Using pimecrolimus cream as a first-line treatment for atopic dermatitis in infants spares the need for topical corticosteroids as frequently and appears safe over the long term, according to a study published online March 23 in Pediatrics. “The efficacy results suggest that pimecrolimus has...
Source: Skin and Allergy News - Category: Dermatology Tags: CME-candidate FPN Journals FPN News FPN Allergy & Immunology FPN Child Adolescent Medicine FPN Dermatology SAN Journals Source Type: news

Related Links:

Allergy Asthma Immunol Res. 2022 Jan;14(1):117-122. doi: 10.4168/aair.2022.14.1.117.ABSTRACTDupilumab was the first biological drug to be approved for adult patients with moderate-to-severe atopic dermatitis (AD), and its use is growing exponentially worldwide. Though its therapeutic efficacy and favorable safety profile have been demonstrated, data on real-world long-term experience with the drug are only beginning to accumulate. Herein, we present a retrospective analysis of Korean patients with moderate-to-severe AD who were treated with dupilumab. We observed excellent overall treatment efficacy with the mean Eczema Ar...
Source: Allergy, Asthma and Immunology Research - Category: Allergy & Immunology Authors: Source Type: research
Allergic contact dermatitis (CD) is a delayed hypersensitivity reaction with keratinocyte-directed cytotoxicity mediated by CD8+ T-cells [1]. Despite association with topical exposure, in rare instances presentation may follow systemic exposure to corticosteroids following prior sensitisation through skin [2]. Among corticosteroids, methylprednisolone and other Coopman group ‘A’ structures classified by structural substitution on C16 of the D ring are thought more immunogenic based on prevalence of reporting [3], but rarity of systemically-induced CD (SCD) has limited investigation of cellular immunopathogenesis.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Tags: Letter to the Editor Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Allergology International - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Allergology International - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Allergology International - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Allergology International - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Arerugi - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Arerugi - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Arerugi - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Even in patients with SPLAD, the most severe AD, TCS-use may be reduced to 2 days per week or less after 3 years with appropriate skin treatment.PMID:34911891 | DOI:10.15036/arerugi.70.1383
Source: Arerugi - Category: Allergy & Immunology Authors: Source Type: research
More News: Allergy | Allergy & Immunology | Children | Corticosteroid Therapy | Dermatitis | Dermatology | Elidel | Pediatrics | Skin | Study